A disproportionality analysis of differences in hypersensitivity reactions to iodinated contrast media using the FDA adverse event reporting system (FAERS)
OBJECTIVE: To compare the disproportionality of hypersensitivity reactions (HSRs) associated with clinically used iodinated contrast media (ICMs) for enhanced patient safety. MATERIALS AND METHODS: We analyzed ICM-related HSR reports from the FDA Adverse Event Reporting System (FAERS) database between the Q1 of 2004 and the Q4 of 2024. Disproportionality analyses were performed to evaluate ICM-related HSR reporting odds ratio and to compare reporting rates of specific HSR subtypes across age, sex, and geographical subgroups. RESULTS: Among 22,375,298 adverse event reports retrieved, 7,515 cases were identified as ICM-induced HSRs. All the studied ICMs were associated with over-reporting frequencies of HSRs, with iopromide showing the highest reporting odds ratio (ROR = 214.11, 95% confidence interval (CI) 197.07 - 232.64). Iopromide and ioversol (ROR = 104.58, 95% CI 93.31 - 117.22) were more likely associated with angioedema than other ICMs, particularly in males and the 45 - 65 age group. Iodixanol (ROR = 17.23, 95% CI 7.95 - 37.34) was associated with the largest disproportionality for severe cutaneous adverse reactions (SCARs), while iodixanol, iopamidol (ROR = 11.90, 95% CI 9.13 - 15.52), and iohexol (ROR = 9.37, 95% CI 7.65 - 11.46) were more likely associated with SCAR than other ICMs, particularly in the 45 - 65 age group. Regarding anaphylactic shock, iopamidol (ROR = 117.18, 95% CI 103.13 - 133.14) and ioversol (ROR = 83.91, 95% CI 74.68 - 133.14) presented a higher disproportionality, especially in males and seniors aged > 65 years. CONCLUSION: The disproportionality signal profiles of ICM-related HSRs vary significantly across specific agents and are influenced by age and sex.
Authors
- Xin‐Ran Qiu
- Daoli Jiang (ORCID: https://orcid.org/0000-0002-5566-6585)
- Jia Han
- Zhen Feng
Publication Details
- Journal
- International Journal of Clinical Pharmacology and Therapeutics
- Published
- 2026-11-18
- DOI
- https://doi.org/10.5414/cp205001
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00